Julie Guillermet-Guibert, team leader of SigDYN is an Inserm Researcher since 2009. The question underlying the following matter, "Which are the distinctive features of cancer cell signalling in physiological conditions and how can we use this knowledge for therapy?", has been the driving force in her career. After obtaining her PhD in 2005, Julie decided to continue her training in UK under the supervision of Prof. Bart Vanhaesebroeck, first in Ludwig Institute of Cancer Research and later in Queen Mary University London (London). During this period, Julie strengthened her knowledge of the biological basis of cell signalling and the utilization of mouse models to mimic a pharmacological intervention. She joined Inserm in 2009 as a permanent researcher with the main objective of studying the unique biological features of cancer cell signalling first in vivo, then modelled ex vivo with an emphasis on the specific pancreatic and ovarian biology. She was awarded an Habilitation by the University Paul Sabatier - Toulouse - in 2015 and then a Jean-Marie Lehn Excellence Prize in 2018 for her work towards a better understanding of resistance to signal-targeted therapies in pancreatic cancer.
“ISI Web of Science Researcher ID: D-2317-2014 / Scopus Author ID: 8847067100 / ORCID ID: D-2317-2014”